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Aims The highly expressed cell adhesion receptor CD29 (b1-integrin) is essential for cardiomyocyte growth and survival,
and its loss of function causes severe heart disease. However, CD29-induced signalling in cardiomyocytes is ill defined
and may involve reactive oxygen species (ROS). A decisive source of cardiac ROS is the abundant NADPH oxidase
(NOX) isoform NOX2. Because understanding of NOX-derived ROS in the heart is still poor, we sought to test the
role of ROS and NOX in CD29-induced survival signalling in cardiomyocytes.
Methods
and results
In neonatal rat ventricular myocytes, CD29 activation induced intracellular ROS formation (oxidative burst) as
assessed by flow cytometry using the redox-sensitive fluorescent dye dichlorodihydrofluorescein diacetate. This
burst was inhibited by apocynin and diphenylene iodonium. Further, activation of CD29 enhanced NOX activity
(lucigenin-enhanced chemiluminescence) and activated the MEK/ERK and PI3K/Akt survival pathways. CD29 also
induced phosphorylation of the inhibitory Ser9 on the pro-apoptotic kinase glycogen synthase kinase-3b in a
PI3K/Akt- and MEK-dependent manner, and improved cardiomyocyte viability under conditions of oxidative stress.
The ROS scavenger MnTMPyP or adenoviral co-overexpression of the antioxidant enzymes superoxide dismutase
and catalase inhibited CD29-induced pro-survival signalling. Further, CD29-induced protective pathways were lost
in mouse cardiomyocytes deficient for NOX2 or functional p47phox, a regulatory subunit of NOX.
Conclusion p47phox-dependent, NOX2-derived ROS are mandatory for CD29-induced pro-survival signalling in cardiomyocytes.
These findings go in line with a growing body of evidence suggesting that ROS can be beneficial to the cell and
support a crucial role for NOX2-derived ROS in cell survival in the heart.
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1. Introduction
Connections to extracellular matrix (ECM) components are essential
for the survival and the structural and functional integrity of cardio-
myocytes.1,2 In particular, transmembrane cell surface adhesion recep-
tors (e.g. integrins) bind ECM proteins such as laminin, collagen, and
fibronectin.3,4 Integrins are heterodimeric transmembrane receptors
composed of an a- and b-subunit. In total, 18 a- and 8 b-chain iso-
forms are known, which form 24 distinct receptors that are in a
bent conformation in quiescent, and in an extended conformation
in activated cells.5,6 The b1-integrin subunit (CD29) represents the
most abundant b-isoform expressed in cardiomyocytes, where it
can dimerize with different a-subunits.7–9 In vitro, CD29 is directly
activated by the binding of ECM components or activating anti-
bodies,10,11 which causes the rearrangement of the actin cytoskeleton
and recruitment of signalling kinases (e.g. mitogen-activated protein
kinases) to the cytosolic part of the integrin receptor4,12. Through ac-
tivation of such signalling kinases, CD29 participates in the regulation
of cardiomyocyte growth and survival. Specifically, CD29 facilitates
a-adrenergic receptor (AR)-stimulated hypertrophy13 and inhibits
b-AR-induced apoptosis in vitro.14,15 In vivo, deletion of CD29 is
embryonically lethal,2,16 and cardiac-specific disruption or knock-out
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leads to disturbed cardiac function, impaired cardiac differentiation, fi-
brosis, and heart failure.16–18 Similarly, mouse hearts deficient in
CD29 exhibit increased cardiac myocyte apoptosis in response to
b-AR stimulation19 and after myocardial infarction20 when compared
with wild-type (wt) hearts. Furthermore, integrin shedding, which is
essential in cardiomyocyte growth, as well as the induction of apopto-
tic processes referred to as anoikis are typical features associated with
the cellular detachment from ECM components.21 Similarly, cell adhe-
sion of a5b1-integrin to fibronectin protects against apoptosis in
modified Chinese hamster ovary cells expressing a5b1-integrin.
22
These studies clearly point out the importance of CD29 in cardio-
myocyte survival, but the understanding of the likely signalling path-
ways involved is poor.
Several studies affirmed the production of reactive oxygen species
(ROS; oxidative burst) by various stimuli, including growth factors or
G protein-coupled receptor agonists as well as by cell adhesion as
seen in anchorage-dependent cell growth.23–26 These ROS act as es-
sential mediators in redox-signalling activating signalling kinases impli-
cated in cell growth, adhesion, and survival. They derive from various
oxidase enzymes, including lipoxygenase, xanthine oxidase, or
NADPH oxidase (NOX), the latter of which is one of the major
sources of cardiac ROS.23,27–29 NOX is a multimeric enzyme that
consists of the cytosolic subunits p40phox, p47phox, p67phox, and
Rac1, all of which translocate to the membrane upon activation, as
well as the transmembrane subunits gp91phox and p22phox. To date,
seven gp91phox homologues, NOX1–5 and DUOX1–2, have been
identified in mammals.30 NOX2 predominates in cardiomyocytes, al-
though NOX1 and NOX4 are also expressed,31 NOX4 being consti-
tutively active even in the absence of the cytosolic subunits. NOX
catalyses a one-electron transfer to molecular oxygen to form the
radical superoxide anion (O †−2 ). O
†−
2 is further reduced to hydrogen
peroxide (H2O2), a reaction that occurs either spontaneously or is
catalysed by superoxide dismutase (SOD), and finally degraded into
water by catalase (cat).
Due to the emerging role of ROS as regulators of cell survival, the
crucial role of NOX as a potent source of ROS in the heart and the
limited understanding of NOX-derived ROS in cardiomyocytes, we
addressed the question if CD29-induced pro-survival signalling
depends on NOX-derived ROS in neonatal cardiomyocytes.
2. Methods
Detailed information on materials and methods is given in the Supplemen-
tary material online.
2.1 Animal material
Wistar rats (2007–2010) were obtained from Harlan Laboratories and
mice from the Jackson Laboratory. From January 2011, Sprague–Dawley
rats originating from in-house breeding were used. All animal protocols
were approved by the Veterinary Department of Basel (Switzerland)
and conformed to the rules of the Swiss Federal Act on Animal Protection
and the National Institutes of Health Guide for the Care and Use of La-
boratory Animals. Neonatal rat ventricular myocytes (NRVMs) were iso-
lated from the hearts of 1- to 3-day-old pups sacrificed by decapitation
and isolation was performed as previously described.32,33 Neonatal
mouse ventricular myocytes (NMVMs) were isolated from 1- to
2-day-old pup hearts of wt (C57BL/6), p47phox loss-of-function (LOF;
homozygous Ncf1m1J) and NOX2 (homozygous Cybbtm1Din) knock-out
strains as previously described.34,35 Genotyping of mouse tails was per-
formed as recommended by the supplier (http://jaxmice.jax.org/pub-cgi/
protocols/protocols.sh). For some experiments, H9c2 cardiomyoblasts
(ATCC) were used.
2.2 Viral transfection
Viral constructs were purchased from the Gene Transfer Vector Core,
University of Iowa, IA, USA. Serum-starved cells were transfected
with the viral constructs Ad5CMVCatalase,36 Ad5CMVSOD137, or
Ad5CMVcytoLacZ38 at concentrations of 50 or 100 multiplicity of infec-
tions (MOIs) for 36 h prior to a-CD29 (10 mg/mL) treatment for
15 min. Expression levels were 1.8+0.3-fold for SOD and 9+1.6-fold
for cat at 50 MOI.
2.3 Western blotting
Sample protein concentrations were estimated using a Pierce protein
BCA kit (Thermo Fisher Scientific). 10–35 mg protein was loaded on a
12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–
PAGE) and transferred onto a polyvinylidene fluoride membrane (GE
Healthcare). Immunoreactive bands were quantified with Image J
version 1.37 (http://rsb.info.nih.gov/ij/).39
2.4 Flow cytometry
Cardiomyocytes were loaded with 12.5 mmol/L (5-(and-6)-chloromethyl-
2′,7′-dichlorodihydrofluorescein diacetate acetyl ester, CM-H2DCF-DA;
Invitrogen) in phenol-red-free (prf) DMEM with Hepes (25 mmol/L)
and L-glutamine (4 mmol/L) for 20 min at 378C with 5% CO2 in the
dark. After washing, cells were detached with accutase (PAA Laborator-
ies) and kept in 500 mL prf-DMEM on ice. Green fluorescence was mea-
sured with FL-1 488 nm excitation and 530 nm emission on a DAKO flow
cytometer and DAKO Summit version 4.3 software.
2.5 Lucigenin assay
NOX activity was measured using lucigenin-enhanced chemiluminescence.
H9c2 cells were treated with a-CD29 antibody or IgG (10 mg/mL,
15 min), then washed three times with cold PBS and scraped into Jude
Krebs buffer (see Supplementary material online) containing protease in-
hibitor cocktail (Roche). Lysates were sonicated (3 s, four times on ice)
and centrifuged at 3000 rpm at 48C for 4 min. Measurements of NOX ac-
tivity were performed by a luminescence assay in a microplate lumi-
nometer using 40 mg of lysate with 5 ml DMSO, 10 mmol/L Lucigenin
(Sigma), 100 mmol/L NAD(P)H (Sigma), and 50 mmol/L Tiron (Fluka)
per well (96-well plate). Data were recorded as relative light units over
time, and integrated and calculated as area under the curve using Image
J software for statistical analysis.
2.6 RNA interference
NRVMs were transfected with 2 mg/106 cells ON-TARGETplus using the
Amaxa Neonatal Rat Cardiomyocytes Nucleofector kit (VPE-1002),
according to the manufacturer’s instructions, and efficiency of knockdown
was assessed using quantitative RT–PCR.
2.7 Cell viability
Cell viability was measured by a tetrazolium (MTT, 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide)-based colorimetric assay using
Cell Proliferation Kit I (Roche) according to the manufacturer’s
instructions.
2.8 Statistical analyses
All statistical analyses were performed in Graphpad Prism version 4.03
and P-values ,0.05 were considered to indicate significant differences.
Significance was tested in repeated measures one-way ANOVA with Bon-
ferroni’s post-test (for sample sizes less than or equal to four) or
Newman–Keuls (for more than four samples to compare) correction.
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For analysing flow cytometry data, the geometric mean was used and
overlays were performed in FloJo software version 7.5.5. (Tri Star Inc.).
3. Results
3.1 CD29 activation induces a
time-dependent oxidative burst, which is
impaired by apocynin and diphenylene
iodonium in cardiomyocytes
To assess whether CD29 activation generates ROS in NRVM,
the redox-sensitive fluorescent dye 5-(and-6)-chloromethyl-2′,7′-
dichlorodihydrofluorescein diacetate acetyl ester (DCF) was used.
Flow cytometry analyses demonstrated a significant increase in
DCF fluorescence indicative of an oxidative burst after 30 min of in-
cubation of NRVM with an activating a-CD29 antibody, which sub-
sided after 2 h (Figure 1A and B). A qualitatively similar increase in
DCF fluorescence was observed in response to exogenous ROS
(H2O2, 100 mmol/L) and to 12-phorbol 13-myristate acetate (PMA,
1 mmol/L), which induces endogenous ROS in other cell types40,41
(Figure 1A).
We further investigated the NOX-dependency of this burst using
the inhibitors apocynin (apo, 500 mmol/L) and diphenylene iodonium
(DPI, 10 mmol/L). Apocynin is, besides known to inhibit the regula-
tory NOX subunit p47phox in leukocytes, implicated as an antioxi-
dant in endothelial and smooth muscle cells,42 and DPI inhibits
flavoenzymes, including NOX.43 Both compounds markedly
decreased DCF fluorescence intensity when administered prior to
a-CD29 (Figure 1C–E).
3.2 CD29 activation induces NOX activity
in cardiomyocytes
As both apocynin and DPI are non-specific, H9c2 cardiomyoblasts
were treated with a-CD29 or non-immune IgG (10 mg/mL,
15 min) and NOX activity was measured by lucigenin-enhanced
chemiluminescence. Cross-linkage of CD29 via activating antibody
significantly enhanced NADPH-dependent lucigenin chemilumines-
cence in H9c2 cells (Figure 2A and B), thus confirming activation
of NOX in response to CD29 stimulation. A similar observation
was made in NRVM plated on dishes precoated with laminin, the
physiological ligand for CD29. These cells exhibited higher NOX ac-
tivity when compared with NRVM plated on non-coated dishes
(data not shown).
3.3 CD29 activation induces
phosphorylation of ERK1/2 (Thr202/
Tyr204), Akt (Ser473), and GSK-3b (Ser9)
CD29 activates the MEK/ERK and the PI3K/Akt pathways in various
cell types.12 In NRVM, increased phosphorylation of ERK and Akt
was observed upon CD29 stimulation, which peaked at 15 min and
was no longer detectable at 45 min (Supplementary material online,
Figure S1A and B). Phosphorylation of serine 9 of glycogen synthase
kinase (GSK)-3b, which is inhibitory to its kinase activity, was used
to measure CD29-induced pro-survival signalling, because (i) it is
involved in the CD29-induced anti-apoptotic effect in adult cardio-
myocytes44 and (ii) it is downstream of the PI3K/Akt pathway.45
Using a phosphorylation site-specific GSK-3b (Ser9) antibody, immu-
noreactive bands were observed at 15 min (Supplementary material
online, Figure S1C). No changes in phosphorylation were detectable
when cardiomyocytes were incubated with either an inhibitory
a-CD29 antibody or with a non-specific IgG (Supplementary material
online, Figure S1A–C).
Figure 1 CD29 activation induces an oxidative burst in NRVM,
which is inhibitable by apocynin and DPI. (A and B) (A) Representa-
tive flow cytometric histograms depict NRVM loaded with the ROS
indicator DCF (12.5 mmol/L). Unstimulated cells (NRVM) without
DCF in black. Fluorescence intensity is shown for unstimulated
cells (NRVM + DCF, orange line) and cardiomyocytes stimulated
with H2O2 (100 mmol/L), PMA (1 mmol/L), or a-CD29 (5 mg/mL)
for 30 min (green line). The shift to the right indicates an increase
in ROS. CD29 activation induced a time-dependent burst that
peaked at 30 min (A and B, 30′) and declined after 2 h (120′, grey
line). (B) Depicts a-CD29-induced fluorescence intensity at different
time points. Data are mean+ SEM. Unless indicated otherwise,
comparisons were not significant. ***P, 0.001 (n ¼ 8). (C–E)
Cells were pretreated (blue) with either apocynin (Apo;
500 mmol/L, 14–16 h), or DPI (10 mmol/L, 45 min) prior to
a-CD29 administration (5 mg/mL, 30 min, C). (D and E) Pretreat-
ment suppressed the a-CD29-induced oxidative burst partially
(apocynin, n ¼ 4) and completely (DPI, n ¼ 5). Data are presented
as mean+ SEM. Unless indicated otherwise, comparisons were
not significant. * and #P, 0.05.
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To further elucidate the pathways of kinase activation upon CD29
stimulation, the MEK inhibitor U0126 (U), the PI3K inhibitors Wort-
mannin (W) and LY294002 (LY), and the Akt inhibitor Akti1/2 (Akti)
were used to inhibit selected parts of the signalling pathway. Of the
four inhibitors, U suppressed the a-CD29-induced phosphorylation
of ERK (Supplementary material online, Figure S2A–D) and W, LY,
and Akti (but not U) suppressed the a-CD29-induced phosphory-
lation of Akt (Supplementary material online, Figure S2E–H). No
cross talk could be observed between the PI3K/Akt and the MEK/
ERK signalling pathways. However, all inhibitors significantly reduced
a-CD29-induced GSK-3b (Ser9) phosphorylation (Supplementary
material online, Figure S2I–L). This observation places GSK-3b
(Ser9) downstream of both the MEK/ERK and the PI3K/Akt pathways.
3.4 CD29-induced pro-survival signalling
is ROS-dependent
Because activation of CD29 induced an oxidative burst in cardiomyo-
cytes (Figure 1), the possibility exists that CD29-stimulated signalling is
ROS-regulated. To test this hypothesis, MnTMPyP (MnT), a mimetic
of the antioxidant enzymes SOD and cat, was used to reduce ROS
levels. Pretreatment with MnT significantly inhibited the
a-CD29-induced phosphorylation of ERK1/2 (Supplementary material
online, Figure S3A), Akt (Supplementary material online, Figure S3B),
and GSK-3b (Supplementary material online, Figure S3C). Similarly,
co-overexpression of SOD and cat using adenoviral constructs signifi-
cantly reduced MEK-, Akt-, and GSK-3b-phosphorylation (Figure 3A–
C ). To assess the respective contribution of O2
†2 and H2O2 to
CD29-induced signalling, similar experiments were performed in
NRVM expressing either SOD or cat. Although either enzyme inhi-
bited phospho-MEK1/2 and phospho-GSK-3b, persistence of
phospho-Akt was observed with overexpression of SOD, but not
of cat, up to 100 MOI (Figure 3D and Supplementary material
online, Figure S4).
3.5 CD29-induced pro-survival signalling
is inhibited by apocynin and DPI
Primarily, a likely role of NOX in CD29-induced survival signalling was
investigated using apo and DPI. Both inhibitors suppressed
CD29-induced ERK1/2- (Supplementary material online, Figure S5A
and D) and Akt-phosphorylation (Supplementary material online,
Figure S5B and E). Although both apo and DPI also inhibited the
CD29-induced GSK-3b phosphorylation, the reliable assessment of
this inhibition is hindered, because both substances affected basal
kinase phosphorylation (Supplementary material online, Figure S5C
and F). However, these findings suggest that NOX might serve as
the source of CD29-induced ROS that trigger ROS-dependent pro-
survival signalling in cardiomyocytes.
3.6 gp91phox- and p47phox-deficient
cardiomyocytes show loss of
a-CD29-induced pro-survival signals
In another set of experiments, NOX was corroborated as source of
ROS by examining a-CD29-induced signalling in NMVMs isolated
from gp91phox (NOX2) knock-out mice and from mice lacking a func-
tional catalytic subunit p47phox. Upon CD29 stimulation, significantly
lower levels of phospho-ERK1/2, phospho-Akt, and phospho-GSK-3b
were observed in NOX2-knock-out mouse cardiomyocytes when
compared with wt (Figure 4A–C). In p47phox LOF NMVM, CD29 ac-
tivation failed to induce phosphorylation of Akt (Ser473; Figure 4E)
and GSK-3b (Ser9; Figure 4F). In contrast, CD29-induced phosphory-
lation of ERK1/2 (Figure 4D) was unaffected by the loss of functional
Figure 2 CD29 induces activation of NOX. H9c2 cells were treated with a-CD29 or non-immune IgG (10 mg/mL) for 15 min and NOX activity
was measured by lucigenin-enhanced chemiluminescence. Kinetics of lucigenin-enhanced chemiluminescence is shown in (B). Basal fluorescence was
measured five times before adding first NAD(P)H and later tiron, respectively (arrows). Data were recorded as relative light units over time and
calculated as area under the curve for statistical analysis (A, n ¼ 3). Data are given as mean+ SEM. **P, 0.01.
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p47phox, suggesting the activation of a p47phox-independent and/or
compensatory pathway.
3.7 The CD29-induced oxidative burst
is impaired in p47phox-LOF, but not in
NOX2-knock-out cardiomyocytes
Because NOX2-derived ROS play an important role in CD29-induced
pro-survival signalling in NMVM, we tested whether the
CD29-induced oxidative burst was impaired in NMVM deficient in
NOX2 or p47phox. Upon activation of CD29, a shift in DCF fluores-
cence was observed in wt NMVM that was missing in p47phox-LOF
NMVM (Figure 5A and C ). In contrast, in NOX2-knock-out cells,
CD29 activation enhanced DCF fluorescence (Figure 5B and D).
Therefore, another p47phox-dependent NOX (e.g. NOX1)46 might
be involved in CD29-induced ROS formation in NMVM.
4. Discussion
This work demonstrates that NOX-derived ROS regulate cardiomyo-
cyte survival pathways. Similar to what has been described for growth
factors and cytokines,29 transient endogenous ROS were formed in
cardiomyocytes in response to CD29 activation (Figure 6) and this
ROS formation was impaired by NOX inhibitors. These findings are
in agreement with DPI-based data implicating NOX in CD29-induced
ROS production in the colic adenocarcinoma cell line (caco-2),47 but
not with findings from mouse embryonic fibroblasts (NIH-3T3),
where synergistically growth factor- and integrin-driven ROS were
mostly lipoxygenase-dependent.48 In cardiac myocytes, however,
Figure 3 CD29-induced pro-survival signalling depends on ROS. (A–C) NRVM were infected with adenoviral constructs to express b-galactosidase
(LacZ100) at 100 MOI or co-overexpress SOD (S50) and cat (C50) at 50 MOI 36 h prior to a-CD29 administration (10 mg/mL, 15 min). Equal protein
amounts were subjected to western blotting using phosphorylation-specific antibodies for MEK1/2 (Ser217/221), Akt (Ser473), and GSK-3b (Ser9).
Data are presented as mean+ SEM. *** and ###P, 0.001, ** and ##P, 0.01, and #P, 0.05 (n ¼ 5 for A and B, n ¼ 3 for C). Unless indicated other-
wise, comparisons were not significant. (D) Western blot of CD29-induced signalling with single-enzyme overexpression at two different MOI, includ-
ing the protein expressions of SOD and cat.
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CD29 activation induced NOX activity and an additional line of evi-
dence for NOX-involvement was obtained using gene knock-outs
(see below).
ROS at moderate levels may serve as signalling molecules partici-
pating in the regulation of cell survival,24,49,50 because of their ability
to activate pro-survival related cascades, including the PI3K/Akt and
the MEK/ERK pathway.51 A prominent target of Akt is GSK3,52 of
which two isoforms, GSK-3a and GSK-3b, are expressed in cardio-
myocytes. Inhibition of GSK-3 via the PI3K pathway promotes cell sur-
vival in Drosophila or neurones.53 Additionally, CD29-dependent,
PI3K-mediated phosphorylation of the inhibitory GSK-3b Ser9 pro-
tects adult rat cardiomyocytes from b-AR-induced apoptosis.44
Although GSK-3b is reportedly directly phosphorylated by Akt,
several other kinases, including the ERK1/2 target p90 ribosomal S6
kinase have also been implicated in GSK-3b inhibition in the
heart.45 Our data show activation of both, the PI3K/Akt and the
MEK/ERK pathway upon CD29 engagement in NRVM and uncover
GSK-3b as a target of both these pathways.
Clearance of ROS by antioxidants elicited apoptotic pathways in
leukaemia cells, inhibiting the phosphorylation of Akt or ERK.54 In
accordance with these findings, co-overexpression of both SOD
and catalase (Figure 3) significantly diminished CD29-induced
phosphorylation of MEK1/2, Akt, and GSK-3b. It is of note that at
higher expression levels single-enzyme overexpression was equally
effective with regard to induced phospho-MEK/ERK and -GSK-3b
inhibition, implicating both O †−2 and H2O2 as second messengers in
CD29-induced pro-survival signal transduction in NRVM. However,
SOD appeared less efficient to suppress Akt-phosphorylation than
catalase. Although this difference could be attributed to the lower ex-
pression levels of SOD, differential regulation of the PI3K/Akt pathway
through O †−2 and H2O2 cannot be ruled out.
DPI and apocynin inhibited the CD29-induced phosphorylation of
ERK1/2, Akt, and GSK-3b, implying NOX-derived ROS as signalling
mediators. Mice carrying either a knock-out of the transmembrane
NADPH oxidase subunit NOX2, or a LOF from the regulatory
subunit p47phox were used to assess whether NOX2 is required for
CD29-induced survival signalling in NMVM. Indeed, NOX2 knock-out
NMVM showed reduced levels of CD29-induced ERK1/2 phosphory-
lation and the CD29-inducible phosphorylation of Akt and GSK-3b
were nearly abolished in both NOX2 knock-out and p47phox-LOF
cardiomyocytes (Figure 4A–F ), highlighting the central role of
NOX2- and p47phox-derived ROS in CD29-induced survival signalling.
In contrast to NOX2 knock-out cardiomyocytes, however, where
CD29-induced ERK-phosphorylation was mostly suppressed,
Figure 4 CD29-induced signal transduction requires NOX2-derived ROS. a-CD29 administration (10 mg/mL, 15 min) induced phosphorylation of
ERK1/2 (p44/42), Akt and GSK-3b in wild-type (wt) NMVM (A–F). a-CD29-induced phosphorylation was absent in NOX2 knock-out (NOX2k.o.)
cardiomyocytes (A–C ); and partially diminished in p47phox loss of function (p47LOF) NMVM (D–F). Data are presented as mean+ SEM. Unless indi-
cated otherwise, comparisons were not significant. * and #P, 0.05, ** and ##P, 0.01, *** and ###P, 0.001 (n ¼ 5 for A, C, and D–F; n ¼ 6 for B).
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induced phospho-ERK was still solid in p47phox-LOF cardiomyocytes.
Although no oxidative burst was detectable in p47phox-LOF cardio-
myocytes at 15 min, i.e. at the time of peak signalling, a compensatory
pathway involving weaker, NOXO1-supported ROS release may
account for ERK activation in the absence of functional p47phox. Alter-
natively, lack of ROS may allow for a ROS-independent pathway to
activate ERK. In fact, co-existence of ROS-dependent and
-independent pathways namely regarding ERK activation has previous-
ly been observed in other cell types.55,56
Interestingly, whereas the CD29-induced oxidative burst was
absent in p47phox-LOF, it was maintained in NOX2 knock-out cardio-
myocytes (Figure 5). Because both NOX1 and NOX2 may use
p47phox to generate ROS in a stimulus-dependent manner,46 preser-
vation of the oxidative burst in the absence of NOX2 implies
another functional NOX homologue (for example NOX1) as an ad-
ditional and/or compensatory ROS source. However, these additional
ROS are unlikely to be involved in CD29-induced survival signalling,
because this signalling is lacking in NOX2 knock-out mice. It is note-
worthy that reciprocal compensation of NOX2 and NOX4 has been
observed in human lung endothelial cells.57 Furthermore, there is evi-
dence for spatiotemporal-defined localization of NOX isoforms at the
plasma membrane (NOX2) or in subcellular compartments (e.g.
endosomes, NOX1 and NOX2)58,59 and different NOX isoforms
may elicit distinct signalling.60 Importantly, NOX2-derived ROS have
been implicated as mediators of cardiomyocyte protection against is-
chaemia/reperfusion injury conferred by ischaemic preconditioning.61
These findings point out the importance of NOX-derived ROS and
are in accordance with our findings that NOX2-derived ROS act as
mediators of pro-survival signalling in cardiomyocytes. In fact, CD29
activation improved survival of NOX2-competent cardiomyocytes
exposed to oxidative stress (H2O2), but appeared not to do so in
NOX2-deficient cells (Supplementary material online, Figure S6). A
Figure 5 Lack of CD29-induced oxidative burst in p47phox-LOF
cardiomyocytes. Serum-starved NMVM were incubated with DCF
(12.5 mmol/L, 20 min) before detaching with accutase. Wt cardio-
myocytes and cells deficient in functional NOX subunits were
treated with a-CD29 antibody (15 mg/mL, 15 min) and DCF inten-
sity was measured by flow cytometry. Representative histograms
of p47phoxLOF (A and C) and NOX2 knock-out (B and D). NMVM
depict untreated wt (black), a-CD29 treated wt (green), untreated
(orange), and treated (blue) (A) p47phoxLOF or (B) NOX2k.o. cardio-
myocytes. Quantified data (C and D) are presented as mean+ SEM.
Unless indicated otherwise, comparisons were not significant.
*P, 0.05; ###P, 0.001 (n ¼ 4 each).
Figure 6 Proposed model for the NOX2- and ROS-dependency of CD29-induced pro-survival signalling in neonatal cardiomyocytes. For details,
see text.
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proposed model for the role of NOX2-derived ROS in
CD29-induced pro-survival signalling in cardiomyocytes is depicted
in Figure 6.
In conclusion, CD29-induced pro-survival signalling in cardiomyo-
cytes is ROS-dependent and NOX2 acts as source of these ROS.
Moreover, CD29-induced inhibition of the pro-apoptotic kinase
GSK-3b depends upon NOX2-derived ROS in rat and mouse cardio-
myocytes. These findings support a beneficial role for NOX2-derived
ROS in cell survival in the heart.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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